Gene News and Research

Latest Gene News and Research

Alzheimer's disease: Gene expression level influences promotion of disorder or protection against development

Using sophisticated techniques that scan the genomes of patients, researchers at the Mayo Clinic campus in Florida have found that a gene appears to either help protect against development of Alzheimer's disease, or promote the disorder depending on the level of gene in the brain.

18 Mar 2010

New findings promise to have fundamental significance in the fight against cancer

Cells have two different protection programs to safeguard them from getting out of control under stress and from dividing without stopping and developing cancer. Until now, researchers assumed that these protective systems were prompted separately from each other.

18 Mar 2010

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

The ALS Therapy Development Institute and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

17 Mar 2010

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it is revising downward its previous sales and earnings guidance for the fiscal year ending September 30, 2010. This action is being taken as a result of weaker than expected operating results for the second quarter ending March 31, 2010, based on preliminary results to date. Separately, Meridian announced that it will file a 510(k) for FDA marketing clearance next week in connection with its illumigene™ C. difficile product.

17 Mar 2010

Finding right balance between high-throughput sequencing and related bioinformatics analysis

Balancing high-throughput sequencing and related bioinformatics analysis between a research group’s internal efforts and specialized service providers can both speed results to difficult biological questions and provide cost-effective access to the latest technology, says Eureka Genomics (EG). The company’s unique capabilities and services and how they can help in “Finding the Right Balance” will be the topic of discussion at a “Java and Jive” session on Wednesday March 17, 8:15 am at the Now-Generation Sequencing conference being held at the Hilton San Diego Resort in San Diego, CA.

17 Mar 2010

Ingenuity Systems selects Biodiagnostics as new distributor of IPA in Greece, Turkey and Balkan countries

Ingenuity Systems, the leading provider of information solutions for life science researchers, has selected Biodiagnostics as its new distributor of IPA® in Greece, Turkey and the Balkan countries. IPA is the leading software application to model, analyze, and understand the complex biological and chemical systems at the core of life science research.

17 Mar 2010

Circulating tumor cells could help guide treatment and improve quality of life for cancer patients

One of the most dangerous characteristics of cancer is its ability to metastasize, or spread through the body. For this reason, oncologists have a major need for better tests to detect cells that break away from primary tumors to travel to other parts of the body.

17 Mar 2010

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix® (clopidogrel) plus aspirin or Effient® (prasugrel) plus aspirin and managed with percutaneous coronary intervention (PCI) following an acute coronary syndrome (ACS) event.

17 Mar 2010

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.

17 Mar 2010

Restoring immune function in HIV patients: Therapies targeting PD-1 and IL-10 molecules needed

New research conducted by the scientific director for VGTI Florida and his colleagues at the University of Montreal, in collaboration with scientists from the NIH and the McGill University Hospital center, may soon lead to an expansion of the drug arsenal used to fight HIV. The research sheds new light on how HIV gradually weakens the body’s immune system and highlights the need for new research into therapies that will target the chain of events that cause the progression of the disease.

17 Mar 2010

Essen Instruments, Origene Technologies partner to co-develop ion channel cell lines

Essen Instruments Inc. and OriGene Technologies, Inc. today announced a strategic alliance to co-develop ion channel cell lines. Essen, based in Ann Arbor Michigan, is a leading provider of life science products and services, including ion channel discovery and safety assays. OriGene, headquartered in Rockville, Maryland, specializes in the creation and supply of gene-centric products, and has a collection of over 30,000 human full length cDNA clones.

17 Mar 2010

Human amniotic fluid skin cells "reprogrammed" to pluripotency

In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.

16 Mar 2010

LUMC purchases Fluidigm Access Array system

Fluidigm Corporation and BIOKÉ, distributor of Fluidigm systems in the Benelux, today announced that Leiden University Medical Center’s (LUMC) Human Genetics Department has purchased a Fluidigm Access Array™ system. The Access Array system enables users to automatically prepare sequencing-ready libraries from up to 48 individual samples at a time, for as little as €7 (EUR) per sample.

16 Mar 2010

Sigma-Aldrich signs agreement to acquire Ace Animals

Sigma-Aldrich® today announced it has signed an agreement to acquire Ace Animals, Inc., a Berks County, PA.-based provider of high quality research rodents to the biomedical industry.

16 Mar 2010

Blocking RhoA enzyme increases survival in SMA mouse model

Scientists from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa have identified a promising new approach for developing drugs to treat Spinal muscular atrophy (SMA), the leading inherited cause of death in infants and toddlers. Dr. Rashmi Kothary and his doctoral student Melissa Bowerman have found that an enzyme called RhoA is overly active in a mouse model of the disease and blocking this enzyme can greatly increase survival. The study is published in Human Molecular Genetics.

16 Mar 2010

Iverson Genetic Diagnostics to conduct WARFARIN clinical study

Iverson Genetic Diagnostics, Inc. today announced that they will conduct a WARFARIN clinical study to assess the efficacy of gene-based testing prior to initiating warfarin anticoagulation therapy to reduce the incidence of bleeding and thromboembolic events.

16 Mar 2010

Epeius Biotechnologies' tumor-targeted vaccine technology for cancer immunotherapy receives patent protection

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe, respectively, and places Epeius Biotech at the forefront of these emerging fields of clinical medicine with best-of-breed solutions and incontrovertible proofs-of-principle in the clinic.

16 Mar 2010

Mathematical model may promote medical research on how to grow new organs

Each cusp of our teeth is regulated by genes which carefully control the development. A similar genetic puzzle also regulates the differentiation of our other organs and of all living organisms.

16 Mar 2010

Dual role of Notch signalling pathway

Scientists headed by ICREA researcher Marco Mil-n, at the Institute for Research in Biomedicine (IRB Barcelona), reveal a surprising new function of Notch protein that contrasts with the one known to date. Found in the cell membrane, this protein activates a signalling pathway that regulates the expression of genes that make the cell divide, grow, migrate, specialise or die.

16 Mar 2010

Keynote speakers to discuss regenerative medicine therapies at upcoming forum

What regenerative medicine therapies are being applied to patients today? What hurdles stand between stem cell therapies and real treatments in the clinic? Keynote speakers at the upcoming inaugural Translational Regenerative Medicine Forum will discuss these topics as well as provide an update on various national and regional stem cell initiatives.

16 Mar 2010

Gene News and Research

Latest Gene News and Research

Alzheimer's disease: Gene expression level influences promotion of disorder or protection against development

New findings promise to have fundamental significance in the fight against cancer

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Finding right balance between high-throughput sequencing and related bioinformatics analysis

Ingenuity Systems selects Biodiagnostics as new distributor of IPA in Greece, Turkey and Balkan countries

Circulating tumor cells could help guide treatment and improve quality of life for cancer patients

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

Restoring immune function in HIV patients: Therapies targeting PD-1 and IL-10 molecules needed

Essen Instruments, Origene Technologies partner to co-develop ion channel cell lines

Human amniotic fluid skin cells "reprogrammed" to pluripotency

LUMC purchases Fluidigm Access Array system

Sigma-Aldrich signs agreement to acquire Ace Animals

Blocking RhoA enzyme increases survival in SMA mouse model

Iverson Genetic Diagnostics to conduct WARFARIN clinical study

Epeius Biotechnologies' tumor-targeted vaccine technology for cancer immunotherapy receives patent protection

Mathematical model may promote medical research on how to grow new organs

Dual role of Notch signalling pathway

Keynote speakers to discuss regenerative medicine therapies at upcoming forum

eBook: Using iPSCs models for human disease research and drug discovery eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS